



japan

value of insight

a consulting & publishing company

Table of Contents

Healthcare System	5
Healthcare Infrastructure	6
Pharmaceutical Market	8
Market Profile and Structure	9
Market Performance and Forecasts	10
Forecasts	11
Regulatory	12
http://www.jpma.or.jp/english/parj/1203.html	13
Approval Procedures	13
Pricing	15
General Procedures	15
<i>Adjustments to Calculated Price</i>	16
<i>Additional Factors in New Drug Pricing</i>	18
Generic Pricing Procedures.....	18
Biennial Price Cuts	19
Price Maintenance System for Patented Drugs	19
Health Technology Assessment (HTA) Board under Consideration	20
Payment	20
Generics	21
Generic Companies.....	21
Generic Market	22
Generic Promotion Efforts.....	23
Biosimilars.....	24
R&D / Clinical Trials	24
Clinical Trial Environment	24
Clinical Trial Regulations	26
Manufacturing	28
Distribution	29
Patent & Intellectual Property Issues	30
Marketing	31

List of Figures

Figure 1 – Population and Economic Statistics	5
Figure 2 – General Healthcare Statistics.....	5
Figure 3 - Types of Health Insurance Organizations	6
Figure 4 - Japanese Physicians by Specialty.....	7
Figure 5 – Demographic Structure.....	8
Figure 6 - Pharmaceutical Market Snapshot.....	8
Figure 7 – Prescription Drug Sales by Channel 2011	10
Figure 8 - Sales of Ethical (Prescription) Drugs in Japan 2004-11; Local and US\$ Values	10
Figure 9 - 2011 Sales by Therapeutic Category.....	11
Figure 10 – Sales of Top 10 Products 2011	11
Figure 11 - PMDA Drug Review Offices and Responsibilities.....	14
Figure 12 – Drug Pricing Process (Non-generics).....	16
Figure 13 – Leading Generic Companies 2010	21
Figure 14 –Generic Penetration Rates 2005-11	22
Figure 15 - Japanese Clinical Trial Starts by Phase (Number and Global Share: 2006-2011).....	26
Figure 16 - Sales of Top 20 Companies 2011 (Distributor Level)	29
Figure 17 – Sales-Force Size (Number of MRs): Top 20 Companies 2010.....	32